Tolerability of Three Local Anesthetic Formulations in Conjunction With NGX-4010 for the Treatment of Neuropathic Pain
Public ClinicalTrials.gov record NCT00082316. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Open-Label Study of the Tolerability of Three Local Anesthetic Formulations in Conjunction With NGX-4010 for the Treatment of Neuropathic Pain
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is a randomized, open-label multi-center evaluation of the tolerability of treatment with NGX-4010 in conjunction with pre-patch topical application of one of three 4% lidocaine-based local anesthetic products. Eligible subjects will have moderate to severe neuropathic pain secondary to painful diabetic neuropathy (PDN), postherpetic neuralgia (PHN) or HIV-associated neuropathy (HIV-AN), with average numeric pain rating scale (NPRS) scores during screening of 3 to 8 (inclusive).
Study identification
- NCT ID
- NCT00082316
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- Not listed
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Not listed
- Primary completion
- Not listed
- Completion
- Not listed
- Last update posted
- Jan 10, 2008
United States locations
- U.S. sites
- 17
- U.S. states
- 12
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| NeurogesX Investigational Site | Huntsville | Alabama | 35801 | — |
| NeurogesX Investigational Site | Mobile | Alabama | 36608 | — |
| NeurogesX Investigational Site | Phoenix | Arizona | 85023 | — |
| NeurogesX Investigational Site | Fountain Valley | California | 92708 | — |
| NeurogesX Investigational Site | Los Gatos | California | 95032 | — |
| NeurogesX Investigational Site | Denver | Colorado | 80209 | — |
| NeurogesX Investigational Site | Clearwater | Florida | 33765 | — |
| NeurogesX Investigational Site | New Port Richey | Florida | 34652 | — |
| NeurogesX Investigational Site | North Miami | Florida | 33161 | — |
| NeurogesX Investigational Site | Plantation | Florida | 33324 | — |
| NeurogesX Investigational Site | West Des Moines | Iowa | 50265 | — |
| NeurogesX Investigational Site | Wellesley Hills | Massachusetts | 02481-2106 | — |
| NeurogesX Investigational Site | St Louis | Missouri | 63108 | — |
| NeurogesX Investigational Site | Greensboro | New Jersey | 27408 | — |
| NeurogesX Investigational Site | Duncansville | Pennsylvania | 16635 | — |
| NeurogesX Investigational Site | San Antonio | Texas | 78229 | — |
| NeurogesX Investigational Site | Salt Lake City | Utah | 84106 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00082316, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 10, 2008 · Synced Sep 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00082316 live on ClinicalTrials.gov.